IBRX. A company with FDA approved drug being shorted: nonsense or has any logic?

I screened into IBRX and I’m on the fence. What caught my eye wasn’t the chart — it was the science. Anktiva targets NK-cell activation. Not gene-editing hype, not preclinical fantasy. It’s FDA-approved and already in patients, which is rare territory for a biotech this size. Here’s where I’m unsure: Biotech execution is brutal. Commercial uptake matters. Oncology timelines are long. And I’m trying to figure out whether the market is missing this — or seeing risks I’m underestimating. Why I haven’t dropped it: • First mover with approval • Multiple cancer indications possible • Other companies entering the same lane (validation?) • Feels early, but not random So I’m asking: Am I early… or just wrong? Not advice, not a pump. Genuinely looking for perspectives from anyone who’s dug into IBRX.